siRNA治疗在妇科肿瘤中应用的研究进展

doi:10.12280/gjfckx.20220961

摘要/Abstract

摘要：

妇科肿瘤在女性各类疾病中的发病率、死亡率均位居前列，且常规治疗后复发、耐药患者预后不佳。小干扰RNA（small interfering RNA，siRNA）能够高效沉默靶向基因，具有基因沉默效率高、合成简便且靶点广泛的优点，是一种有应用前景的治疗基因相关疾病的工具。但临床应用siRNA药物还需面对裸序列不稳定、体内传送效率低以及不可控的不良反应等问题。近年来，关于选择何种载体以实现体内递送siRNA药物以及如何选择合适的应用靶点，是针对siRNA治疗的研究焦点。综述近年来有关载体修饰siRNA药物在妇科肿瘤治疗中的应用，以及各类妇科肿瘤中siRNA重要的潜在应用靶点的研究进展。

关键词: 生殖器肿瘤, 女（雌）性, RNA, 小分子干扰, 基因治疗, 诊断治疗纳米医学, 分子靶向治疗

Abstract:

Gynecologic tumors are among the leading diseases in women in terms of morbidity and mortality, and patients with recurrence and drug resistance after conventional treatment have poor prognosis. Small interfering RNA (siRNA) is a promising tool for the treatment of gene-related diseases because of its high efficiency in gene silencing, ease of synthesis and wide range of targets. However, the clinical application of siRNA drugs still needs to face the problems of bare sequence instability, low in vivo delivery efficiency, and uncontrollable adverse effects. In recent years, the choice of vectors for in vivo delivery of siRNA drugs and the selection of suitable targets for their application have been the focus of research on siRNA therapeutics. This paper mainly reviews the recent research progress about the application of vector-modified siRNA drugs in gynecologic tumor therapy and the important potential application targets of siRNA in various gynecologic tumors.

Key words: Genital neoplasms, female, RNA, small interfering, Genetic therapy, Theranostic nanomedicine, Molecular targeted therapy

罗燕, 孙格格, 韩丽婷, 李新. siRNA治疗在妇科肿瘤中应用的研究进展[J]. 国际妇产科学杂志, 2023, 50(2): 211-215.

LUO Yan, SUN Ge-ge, HAN Li-ting, LI Xin. Research Advances in the Application of siRNA Therapy in Gynecologic Tumors[J]. Journal of International Obstetrics and Gynecology, 2023, 50(2): 211-215.

参考文献 34

[1]	Siegel RL, Miller KD, Fuchs HE, et al. Cancer Statistics, 2021[J]. CA Cancer J Clin, 2021, 1(1):7-33. doi: 10.3322/caac.21654. doi: 10.3322/caac.21654
[2]	Adams D, Gonzalez-Duarte A, O′Riordan WD, et al. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis[J]. N Engl J Med, 2018, 379(1):11-21. doi: 10.1056/NEJMoa1716153. doi: 10.1056/NEJMoa1716153
[3]	Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans[J]. Nature, 1998, 391(6669):806-811. doi: 10.1038/35888. doi: 10.1038/35888
[4]	Sajid MI, Moazzam M, Kato S, et al. Overcoming Barriers for siRNA Therapeutics: From Bench to Bedside[J]. Pharmaceuticals (Basel), 2020, 13(10):294. doi: 10.3390/ph13100294. doi: 10.3390/ph13100294
[5]	Chen J, Zhao S, Tan W, et al. Attenuated Salmonella carrying plasmid co-expressing HPV16 L1 and siRNA-E6 for cervical cancer therapy[J]. Sci Rep, 2021, 11(1):20083. doi: 10.1038/s41598-021-99425-3. doi: 10.1038/s41598-021-99425-3 pmid: 34635698
[6]	Xu C, Liu W, Hu Y, et al. Bioinspired tumor-homing nanoplatform for co-delivery of paclitaxel and siRNA-E7 to HPV-related cervical malignancies for synergistic therapy[J]. Theranostics, 2020, 10(7):3325-3339. doi: 10.7150/thno.41228. doi: 10.7150/thno.41228 pmid: 32194871
[7]	Singh MS, Ramishetti S, Landesman-Milo D, et al. Therapeutic Gene Silencing Using Targeted Lipid Nanoparticles in Metastatic Ovarian Cancer[J]. Small, 2021, 17(19):e2100287. doi: 10.1002/smll.202100287. doi: 10.1002/smll.202100287
[8]	Xia Y, Tang G, Wang C, et al. Functionalized selenium nanoparticles for targeted siRNA delivery silence Derlin1 and promote antitumor efficacy against cervical cancer[J]. Drug Deliv, 2020, 27(1):15-25. doi: 10.1080/10717544.2019.1667452. doi: 10.1080/10717544.2019.1667452 pmid: 31830840
[9]	Wang C, Xia Y, Huo S, et al. Silencing of MEF2D by siRNA Loaded Selenium Nanoparticles for Ovarian Cancer Therapy[J]. Int J Nanomedicine, 2020, 15:9759-9770. doi: 10.2147/IJN.S270441. doi: 10.2147/IJN.S270441
[10]	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424. doi: 10.3322/caac.21492. doi: 10.3322/caac.21492
[11]	Zhao S, Huang L, Basu P, et al. Cervical cancer burden, status of implementation and challenges of cervical cancer screening in Association of Southeast Asian Nations (ASEAN) countries[J]. Cancer Lett, 2022, 525:22-32. doi: 10.1016/j.canlet.2021.10.036. doi: 10.1016/j.canlet.2021.10.036
[12]	Bian S, Zhao Y, Li F, et al. Knockdown of p62/sequestosome enhances ginsenoside Rh2-induced apoptosis in cervical cancer HeLa cells with no effect on autophagy[J]. Biosci Biotechnol Biochem, 2021, 85(5):1097-1103. doi: 10.1093/bbb/zbab019. doi: 10.1093/bbb/zbab019
[13]	Meiners A, Bäcker S, Hadrović I, et al. Specific inhibition of the Survivin-CRM1 interaction by peptide-modified molecular tweezers[J]. Nat Commun, 2021, 12(1):1505. doi: 10.1038/s41467-021-21753-9. doi: 10.1038/s41467-021-21753-9 pmid: 33686072
[14]	Mikulandra M, Kobescak A, Verillaud B, et al. Radio-sensitization of head and neck cancer cells by a combination of poly(I:C) and cisplatin through downregulation of survivin and c-IAP2[J]. Cell Oncol(Dordr), 2019, 42(1):29-40. doi: 10.1007/s13402-018-0403-7. doi: 10.1007/s13402-018-0403-7
[15]	Zhou J, Guo X, Chen W, et al. Targeting survivin sensitizes cervical cancer cells to radiation treatment[J]. Bioengineered, 2020, 11(1):130-140. doi: 10.1080/21655979.2020.1717297. doi: 10.1080/21655979.2020.1717297 pmid: 31959045
[16]	Xi M, Tang W. Knockdown of Ezrin inhibited migration and invasion of cervical cancer cells in vitro[J]. Int J Immunopathol Pharmacol, 2020, 34: 2058738420930899. doi: 10.1177/2058738420930899. doi: 10.1177/2058738420930899
[17]	Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: Evolution of management in the era of precision medicine[J]. CA Cancer J Clin, 2019, 69(4):280-304. doi: 10.3322/caac.21559. doi: 10.3322/caac.21559
[18]	Zhang X, Wang LL, Wang B, et al. Effect of siRNA-induced Atg7 gene silencing on the sensitivity of ovarian cancer SKOV3 cells to cisplatin[J]. Am J Transl Res, 2020, 12(5):2052-2061. pmid: 32509199
[19]	Reyes-González JM, Quiñones-Díaz BI, Santana Y, et al. Downstream Effectors of ILK in Cisplatin-Resistant Ovarian Cancer[J]. Cancers (Basel), 2020, 12(4):880. doi: 10.3390/cancers12040880. doi: 10.3390/cancers12040880
[20]	Löblein MT, Falke I, Eich HT, et al. Dual Knockdown of Musashi RNA-Binding Proteins MSI-1 and MSI-2 Attenuates Putative Cancer Stem Cell Characteristics and Therapy Resistance in Ovarian Cancer Cells[J]. Int J Mol Sci, 2021, 22(21):11502. doi: 10.3390/ijms222111502. doi: 10.3390/ijms222111502
[21]	Troschel FM, Palenta H, Borrmann K, et al. Knockdown of the prognostic cancer stem cell marker Musashi-1 decreases radio-resistance while enhancing apoptosis in hormone receptor-positive breast cancer cells via p21WAF1/CIP1[J]. J Cancer Res Clin Oncol, 2021, 147(11):3299-3312. doi: 10.1007/s00432-021-03743-y. doi: 10.1007/s00432-021-03743-y pmid: 34291358
[22]	Troschel FM, Minte A, Ismail YM, et al. Knockdown of Musashi RNA Binding Proteins Decreases Radioresistance but Enhances Cell Motility and Invasion in Triple-Negative Breast Cancer[J]. Int J Mol Sci, 2020, 21(6): 2169. doi: 10.3390/ijms21062169. doi: 10.3390/ijms21062169
[23]	Ghareghomi S, Ahmadian S, Zarghami N, et al. hTERT-molecular targeted therapy of ovarian cancer cells via folate-functionalized PLGA nanoparticles co-loaded with MNPs/siRNA/wortmannin[J]. Life Sci, 2021, 277:119621. doi: 10.1016/j.lfs.2021.119621. doi: 10.1016/j.lfs.2021.119621
[24]	Braun MM, Overbeek-Wager EA, Grumbo RJ. Diagnosis and Management of Endometrial Cancer[J]. Am Fam Physician, 2016, 93(6):468-474. pmid: 26977831
[25]	Makker V, MacKay H, Ray-Coquard I, et al. Endometrial cancer[J]. Nat Rev Dis Primers, 2021, 7(1):88. doi: 10.1038/s41572-021-00324-8. doi: 10.1038/s41572-021-00324-8 pmid: 34887451
[26]	Suzuki H, Boki H, Kamijo H, et al. YKL-40 Promotes Proliferation of Cutaneous T-Cell Lymphoma Tumor Cells through Extracellular Signal-Regulated Kinase Pathways[J]. J Invest Dermatol, 2020, 140(4):860-868.e3. doi: 10.1016/j.jid.2019.09.007. doi: S0022-202X(19)33298-1 pmid: 31622598
[27]	Chen HY, Zhou ZY, Luo YL, et al. Knockdown of YKL-40 inhibits angiogenesis through regulation of VEGF/VEGFR2 and ERK1/2 signaling in endometrial cancer[J]. Cell Biol Int, 2021, 45(12):2557-2566. doi: 10.1002/cbin.11699. doi: 10.1002/cbin.11699
[28]	Luo Q, Fan J, Li L. Silencing YKL-40 gene can inhibit inflammatory factor expression and affects the effect of THP-1 cells on endometrial cancer[J]. Arch Gynecol Obstet, 2022, 305(2):467-473. doi: 10.1007/s00404-021-06194-5. doi: 10.1007/s00404-021-06194-5
[29]	Falke I, Troschel FM, Palenta H, et al. Knockdown of the stem cell marker Musashi-1 inhibits endometrial cancer growth and sensitizes cells to radiation[J]. Stem Cell Res Ther, 2022, 13(1):212. doi: 10.1186/s13287-022-02891-3. doi: 10.1186/s13287-022-02891-3 pmid: 35619161
[30]	Wei M, Zhang Y, Yang X, et al. Claudin-2 promotes colorectal cancer growth and metastasis by suppressing NDRG1 transcription[J]. Clin Transl Med, 2021, 11(12):e667. doi: 10.1002/ctm2.667. doi: 10.1002/ctm2.667 pmid: 34965023
[31]	Okada T, Konno T, Kohno T, et al. Possibility of Targeting Claudin-2 in Therapy for Human Endometrioid Endometrial Carcinoma[J]. Reprod Sci, 2020, 27(11):2092-2103. doi: 10.1007/s43032-020-00230-6. doi: 10.1007/s43032-020-00230-6 pmid: 32548807
[32]	Zhang Y, Xie X, Yeganeh PN, et al. Immunotherapy for breast cancer using EpCAM aptamer tumor-targeted gene knockdown[J]. Proc Natl Acad Sci U S A, 2021, 118(9):e2022830118. doi: 10.1073/pnas.2022830118. doi: 10.1073/pnas.2022830118
[33]	Meng Z, Lu M. RNA Interference-Induced Innate Immunity, Off-Target Effect, or Immune Adjuvant?[J]. Front Immunol, 2017, 8:331. doi: 10.3389/fimmu.2017.00331. doi: 10.3389/fimmu.2017.00331 pmid: 28386261
[34]	Lin X, Ruan X, Anderson MG, et al. siRNA-mediated off-target gene silencing triggered by a 7 nt complementation[J]. Nucleic Acids Res, 2005, 33(14):4527-4535. doi: 10.1093/nar/gki762. doi: 10.1093/nar/gki762 pmid: 16091630